Bruker Corp at Barclays Global Healthcare Conference Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Luke Sergott - Barclays - Analyst : <_ALACRA_META_ABSTRACT>I guess we'll start off, I mean, the topic du jour obviously is the academic and government markets, the health of those. You're a global business. We'll, I'm sure, touch on the NIH piece first, but talk about the news in Germany from the weekend on the incoming party proposing their highlights on the defense side, where their investments are being made, and just kind of bring it forward to like, hey, this is a global business and --

Question: Luke Sergott - Barclays - Analyst : Yeah. So have you started to see orders or projects start to flow in and kind of the RFP process starting yet? Or is this just kind of headline?

Question: Luke Sergott - Barclays - Analyst : All right. Just more indicative, okay.

Question: Luke Sergott - Barclays - Analyst : That makes sense. On the more near term on the NIH and academic, kind of walk through what you guys have baked in on your guide and how you're thinking about it. And just what are you hearing from customers right now? The doom-and-gloom message is pretty clear.

Question: Luke Sergott - Barclays - Analyst : And so as you think about that 8%, being down 8%, I assume that with the way the quarter's shaping out with how you guys look at it, just talk about the kind of pacing that you've seen from order demand throughout your quarter from Jan to Feb to March. Because, typically, your back -- I'd say, 40% of your quarter comes in like the last month, month and a half, or something like that or --

Question: Luke Sergott - Barclays - Analyst : Got it.

Question: Luke Sergott - Barclays - Analyst : And if you dig in on kind of where you think the most pressure's going to come from, the genomics piece nano string versus your high-end instrumentation in the UHF, try to bucket out where you would see most of that pressure here as we come into 1Q where you're looking for flattish organic, what would be kind of the immediate impacts right now from an application perspective versus ones that can actually be kind of pushed out even further? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 11, 2025 / 6:30PM, BRKR.OQ - Bruker Corp at Barclays Global Healthcare Conference

Question: Luke Sergott - Barclays - Analyst : Yeah. Sure. And I guess when you're thinking about you're laying out a product road map or application road map for better discovery multiomics, everything like that, is there a chance there, from a pharma perspective, that they can pick up some of the slack? From a proteomic side, they, I would say been behind the curve versus the academia where, now they're all genomics, but is there something where you can ultimately push further into that given now that you have a nano string --

Question: Luke Sergott - Barclays - Analyst : And so after this period of restructuring rationalization and tighter budgets, they're still spending on those technologies that helped them discover the drugs and so this could really kind of --

Question: Luke Sergott - Barclays - Analyst : Got you. And then lastly here was, last couple of minutes, when you think about heading into the year as well on your guide how much has been -- how conservative have you been on the China piece, so update us on China, the stimulus activity you guys have already seen a couple orders there, has that continued to pick up that was kind of where you were being conservative where it could offset some of this academic headwinds, so give us an update on the China side.

Question: Luke Sergott - Barclays - Analyst : Got you. That's all the time. Thank you.